Verona Pharma PLC Files Statement for Proposed Global Offering (4837B)
April 04 2017 - 1:14AM
UK Regulatory
TIDMVRP
RNS Number : 4837B
Verona Pharma PLC
04 April 2017
FOR RNS RELEASE:
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
Verona Pharma Files Registration Statement for Proposed Global
Offering
4 April, 2017, London - Verona Pharma plc (AIM: VRP.L) ("Verona
Pharma"), a clinical-stage biopharmaceutical company focused on
developing and commercialising innovative therapeutics for the
treatment of respiratory diseases with significant unmet medical
needs, announced today the filing of a registration statement on
Form F-1 with the U.S. Securities Exchange Commission ("SEC")
relating to a proposed initial public offering of its American
Depositary Shares ("ADSs"), representing ordinary shares, in the
United States and a proposed concurrent private placement of its
ordinary shares in Europe and other countries outside of the United
States and Canada (together, the "Global Offering"). All ADSs and
ordinary shares to be sold in the Global Offering will be offered
by Verona Pharma. The number of ordinary shares to be represented
by each ADS, the number of ADSs and ordinary shares to be offered
and the price range for the Global Offering have not yet been
determined. Verona Pharma has applied to have its ADSs listed on
the NASDAQ Global Market under the symbol "VRNA". Upon completion
of the Global Offering, Verona Pharma's ordinary shares will
continue to be admitted to trading on the AIM market of the London
Stock Exchange under the symbol "VRP".
Jefferies and Stifel are acting as joint book-running managers
for the Global Offering. Wedbush PacGrow and SunTrust Robinson
Humphrey are acting as co-managers.
The Global Offering will be made only by means of a prospectus.
When available, copies of the preliminary prospectus relating to
and describing the terms of the Global Offering may be obtained
from the offices of Jefferies LLC, Attention: Equity Syndicate
Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY
10022, or by telephone at (877) 547-6340, or by e-mail at
Prospectus_Department@Jefferies.com; or from Stifel, Nicolaus &
Company, Incorporated, Attention: Syndicate, One Montgomery Street,
Suite 3700, San Francisco, California 94104, or by telephone at
(415) 364-2720, or by e-mail at syndprospectus@stifel.com.
A registration statement relating to these securities has been
filed with the SEC but has not yet become effective. These
securities may not be sold, nor may offers to buy these securities
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
Forward Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including without limitation statements regarding our
plans to conduct the Global Offering.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from our
expectations expressed or implied by the forward-looking
statements, including, but not limited to, the following: we may
determine not to conduct a registered initial public offering in
the time frame that we currently expect or at all, due to a number
of potential important factors, including conditions in the U.S.
capital markets, negative global economic conditions, potential
negative developments in our clinical trials or research programs,
other negative developments in our business, or unfavorable
legislative or regulatory developments.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this
press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
For readers in the European Economic Area
In any EEA Member State that has implemented the Prospectus
Directive (as defined below), this communication is only addressed
to and directed at qualified investors in that Member State within
the meaning of the Prospectus Directive. The term "Prospectus
Directive" means Directive 2003/71/EC (and amendments thereto,
including Directive 2010/73/EU, to the extent implemented in each
relevant Member State), together with any relevant implementing
measure in the relevant Member State.
For readers in the United Kingdom
This communication, in so far as it constitutes an invitation or
inducement to enter into investment activity (within the meaning of
section 21 of the Financial Services and Markets Act 2000 as
amended) in connection with the securities which are the subject of
the offering described in this press release or otherwise, is being
directed only at (i) persons who are outside the United Kingdom or
(ii) persons who have professional experience in matters relating
to investments who fall within Article 19(5) ("Investment
professionals") of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) certain
high value persons and entitles who fall within Article 49(2)(a) to
(d) ("High net worth companies, unincorporated associations etc.")
of the Order; or (iv) any other person to whom it may lawfully be
communicated (all such persons in (i) to (iv) together being
referred to as "relevant persons"). The ADSs or ordinary shares
offered in the Global Offering are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise
acquire such ADSs or ordinary shares will be engaged in only with
relevant persons. Any person who is not a relevant person should
not act or rely on this document or any of its contents.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283
4200
Jan-Anders Karlsson, Chief Executive info@veronapharma.com
Officer
N+1 Singer (Nominated Adviser Tel: +44 (0)20 7496
and UK Broker) 3000
Aubrey Powell / James White
FTI Consulting (UK Media and Tel: +44 (0)20 3727
Investor enquiries) 1000
Simon Conway / Stephanie Cuthbert veronapharma@fticonsulting.com
/
Natalie Garland-Collins
ICR, Inc. (US Media and Investor
enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUSANRBRASRRR
(END) Dow Jones Newswires
April 04, 2017 02:14 ET (06:14 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024